Last reviewed · How we verify
NCT06573892: GMCHF
The Gut Microbiome in Chronic Heart Failure
NA trial testing Probiotic in Heart Failure in 90 participants. Currently enrolling.
25 December 2024
Quick facts
| Lead sponsor | Nazarbayev University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 90 |
| Start date | 1 October 2024 |
| Primary completion | 25 December 2024 |
| Estimated completion | 31 October 2025 |
| Sites | 1 location across Kazakhstan |
Drugs / interventions tested
- Probiotic
- Placebo
Conditions studied
- Heart Failure — all drugs for Heart Failure →
Sponsor
Nazarbayev University
Who can join
18 and older, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
there are numerous studies, most of which are predominantly associative in nature, investigating the association between the gut microbiota and various pathologies. However, to establish a causal relationship between microbiome composition and chronic heart failure (HF), clinical studies are needed, particularly using probiotics that can modify the composition and function of the gut microbiota. Examining their effects on HF can help understand which specific changes are associated with improvement or slowing the progression of the disease. The gut microbiome plays an important role in regulating the immune system and inflammatory processes. Investigating the impact of probiotics on these mechanisms may reveal their potential anti-inflammatory and immunomodulatory properties, which can be beneficial for controlling the inflammation characteristic of HF. Additionally, studying the interaction of probiotics with other medications, such as antihypertensive and diuretic agents, can be crucial for optimizing pharmacotherapy in HF patients. Confirming the role of the gut microbiota in the pathogenesis of HF and further developing probiotic therapy may lead to improved prognosis and treatment outcomes for HF patients. Overall, conducting a clinical study using probiotics in HF has the potential to expand our knowledge of the role of the gut microbiota in this disease and lay the groundwork for the development of new treatment strategies.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Polyphenol-mediated microbiome modulation in STEMI patients: a pilot study.
Issilbayeva A, Sergazy S, Zhashkeyev A, Gulyayev A, et al · · 2025 · cited 1× · PMID 40470050 · DOI 10.3389/fmed.2025.1522373
Verify or expand the search:
- PubMed search for NCT06573892
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Probiotic
Trials testing the same drug.
- NCT07529457 — Akk09 in Adults With Constipation · NA · not yet recruiting
- NCT07507955 — Probiotics for Constipation Relief in Adults · NA · not yet recruiting
- NCT07462481 — Probiotic Improve Constipation · NA · recruiting
- NCT07511855 — Stress-buffering and Sleep Disturbance-resilient Effects of a Dual Bifidobacterium Longum Combination Under Short-term T · Phase 2 · not yet recruiting
- NCT07474064 — Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC · Phase 2 · not yet recruiting
Other recruiting trials for Heart Failure
Currently open trials in the same condition.
- NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
- NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
- NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
- NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
- NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
Other Nazarbayev University trials
Trials by the same sponsor.
- NCT07419711 — Grape Polyphenols for Prevention of Chemotherapy-Induced Cardiotoxicity · NA · not yet recruiting
- NCT07111819 — Cervical Cancer Screening Via Self-sampling · NA · not yet recruiting
- NCT06721182 — Effectiveness of REBOA in Reducing Blood Loss During Cesarean Section in Patients with PAS · NA · not yet recruiting
- NCT07303556 — Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs · NA · active not recruiting
- NCT06622928 — Ventriculo-Arterial Coupling and Intra-Dialytic Changes in Hemodialysis Patients: Prognostic Insights · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06573892 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nazarbayev University
- Last refreshed: 27 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06573892.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing